Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens

Leukemia. 2011 Jul;25(7):1197-200. doi: 10.1038/leu.2011.57. Epub 2011 Apr 1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzenesulfonates / pharmacology*
  • Binding, Competitive
  • Clinical Trials, Phase II as Topic
  • Cytarabine / pharmacology*
  • Drug Synergism
  • Eukaryotic Initiation Factor-4E / antagonists & inhibitors*
  • Humans
  • Idarubicin / pharmacology*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myelomonocytic, Acute / drug therapy*
  • Leukemia, Myelomonocytic, Acute / pathology
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / pharmacology*
  • RNA Caps / antagonists & inhibitors
  • RNA Caps / metabolism
  • Ribavirin / metabolism
  • Ribavirin / pharmacology*
  • Ribavirin / therapeutic use
  • Sorafenib
  • Tumor Cells, Cultured / drug effects
  • Tumor Stem Cell Assay

Substances

  • Benzenesulfonates
  • Eukaryotic Initiation Factor-4E
  • Phenylurea Compounds
  • Pyridines
  • RNA Caps
  • Cytarabine
  • Niacinamide
  • Ribavirin
  • Sorafenib
  • Idarubicin